• Dimethoxy-Tolazoline Derivatives: Selectivity at α-Adrenorec

  2026-07-12

  This study systematically mapped how different positions of dimethoxy substitution on tolazoline alter its activity at α1- and α2-adrenoreceptors in vitro. The findings establish these substituted tolazoline derivatives as valuable tools for dissecting adrenergic receptor signaling, with direct implications for experimental design in neurovascular and islet function research.

• Haloprogin’s Broad-Spectrum Antifungal Properties: Insights

  2026-07-10

  The 1970 study by Harrison et al. established Haloprogin as an innovative topical agent with robust activity against dermatophytes, yeasts, and selective Gram-positive bacteria. Its comparative performance versus tolnaftate, combined with unique antimonilial and antibacterial properties, made it a pivotal molecule for dermatophytosis and Candida research.

• Foretinib (GSK1363089): Strategic Horizons in Translational

  2026-07-09

  Explore how Foretinib (GSK1363089) is shaping next-generation cancer research by integrating mechanistic rigor with translational opportunity. This article decodes the inhibitor’s multikinase action, guides protocol design, and charts a visionary path for tumor growth and metastasis modeling—bridging experimental complexity, workflow reproducibility, and the evolving competitive landscape.

• SB743921: Advanced Kinesin Spindle Protein Inhibitor Workflo

  2026-07-09

  SB743921 stands out as a best-in-class kinesin spindle protein inhibitor, enabling precise induction of mitotic arrest and apoptosis in cancer research. This article unpacks actionable workflows, troubleshooting strategies, and translational insights for leveraging SB743921—available from APExBIO—in both in vitro and in vivo models.

• Lisinopril Dihydrate: Applied ACE Inhibitor Workflows in Res

  2026-07-08

  Lisinopril dihydrate, a high-purity long-acting ACE inhibitor from APExBIO, empowers cardiovascular and renal research with exceptional specificity and reproducibility. This article delivers actionable protocols, troubleshooting insights, and evidence-based strategies to maximize translational impact across hypertension, heart failure, and nephropathy models.

• Adipose-Neural Axis Drives Epicardial Fat-Linked Arrhythmias

  2026-07-08

  Fan et al. (2024) establish a stem cell-based in vitro model demonstrating that the adipose-neural axis, particularly via leptin and neuropeptide Y (NPY) signaling, is a key driver of cardiac arrhythmias associated with epicardial adipose tissue (EAT). Their mechanistic work identifies specific molecular targets and suggests new avenues for arrhythmia intervention.

• Annexin V-Cy5/DAPI Apoptosis Kit: Precision in Apoptosis Det

  2026-07-07

  The Annexin V-Cy5/DAPI Apoptosis Kit enables rapid, highly specific detection of apoptosis and necrosis in diverse cellular models. Its streamlined protocol and dual-fluorescence design accelerate mechanistic discoveries, as exemplified in recent leukemia research.

• Lipid Peroxidation (MDA) Assay Kit: Assay Optimization and T

  2026-07-07

  Explore the Lipid Peroxidation (MDA) Assay Kit as a robust platform for malondialdehyde quantification and translational research. Gain insights into assay optimization, recent advances in ferroptosis, and the clinical relevance of lipid peroxidation measurement.

• Sulfachloropyridazine: Mechanism, Research Use, and Evidence

  2026-07-06

  Sulfachloropyridazine is a sulfonamide antibacterial agent and a potent, specific inhibitor of bacterial dihydropteroate synthase. Peer-reviewed studies and product data confirm its value in enzyme inhibition assays, antimicrobial susceptibility testing, and microbiome research. Its validated activity against key pathogens makes it a reliable choice in both mechanistic and applied research contexts.

• Dual Ubiquitin Binding by SPRTN Enables Rapid DPC Proteolysi

  2026-07-06

  This study elucidates how the SPRTN protease achieves specificity and rapid activity in the removal of polyubiquitinated DNA-protein crosslinks (DPCs), a critical genome maintenance process. Through structural and biochemical analyses, the authors demonstrate that SPRTN’s newly defined ubiquitin-binding domain is essential for recognizing and processing DPCs, offering mechanistic insights with potential applications in proteomic workflows and redox-controlled assays.

• Sulfachloropyridazine (SKU BA1082): Reproducibility in Lab A

  2026-07-05

  Explore how Sulfachloropyridazine (SKU BA1082) from APExBIO addresses laboratory challenges in cell viability, microbial susceptibility, and enzyme inhibition workflows. This scenario-driven guide provides evidence-based answers to real experimental hurdles, ensuring data reproducibility and workflow confidence for biomedical researchers.

• Topotecan HCl: Advanced Mechanistic Insights for DNA Damage-

  2026-07-04

  Explore Topotecan HCl as a topoisomerase 1 inhibitor with a focus on DNA damage mechanisms and selective cellular vulnerability. This article uniquely bridges molecular pharmacology with the latest discoveries in DNA repair and neuroinflammation, offering fresh perspectives for cancer research.

• Sulfachloropyridazine Alters Cecal Microbiota in E. tenella

  2026-07-03

  This study uses 16S rRNA sequencing and metabolomics to elucidate how sulfachloropyridazine, ethanamizuril, and their combination modulate the cecal microbiota and metabolic landscape in chickens infected with Eimeria tenella. The findings reveal drug-specific effects on pathogenic and commensal bacteria, offering new system-level perspectives for monitoring anticoccidial therapy efficacy.

• Scalable iMSC-EV Biomanufacturing for Pulmonary Fibrosis The

  2026-07-03

  This study presents a scalable, standardized platform for producing extracellular vesicles (EVs) from extended pluripotent stem cell-derived mesenchymal stem cells (iMSCs) using bioreactor technology. The approach addresses key challenges in EV therapeutics by enabling consistent, large-scale production while maintaining therapeutic efficacy, particularly in pulmonary fibrosis models.

• LNP-mRNA-Engineered Fibroblasts Target Inflammatory IVDD Pat

  2026-07-02

  This study introduces a dual-therapeutic strategy utilizing lipid nanoparticle (LNP)-delivered mRNA to engineer fibroblasts for targeted delivery of TNF-α antibodies in intervertebral disc degeneration (IVDD). The approach effectively modulates the inflammatory microenvironment and restores disc structure in preclinical models, offering mechanistic and translational insights for regenerative therapies.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page